All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Lurbinectedin Exhibits Encouraging Efficacy, Signaling Forward Momentum in SCLC Management

September 26th 2022

The field of relapsed/refractory small cell lung cancer is expanding to include novel options for disease management, most notably, the chemotherapy lurbinectedin.

TAC01-HER2 Showcases Early Clinical Activity in HER2-Overexpressed Solid Tumors

September 25th 2022

TAC01-HER2 demonstrated early signals of clinical activity with a tolerable safety profile in patients with HER2-overexpressed solid tumors.

Pembrolizumab Plus Chemotherapy Drives Durable PFS, OS Benefit in Squamous NSCLC

September 24th 2022

Pembrolizumab plus chemotherapy demonstrated sustained improvements in progression-free survival and overall survival vs placebo plus chemotherapy in patients with treatment-naïve, metastatic squamous non–small cell lung cancer regardless of PD-L1 expression level.

Physicians Lose Access to 3 PARP Inhibitors for Heavily Pretreated, BRCA-Mutated Advanced Ovarian Cancer

September 23rd 2022

Manufacturers of 3 PARP inhibitors—niraparib, olaparib, and rucaparib—have voluntarily withdrawn indications for heavily pretreated patients with BRCA-mutated ovarian cancer due to safety concerns.

FDA Grants Fast Track Designation to Ficlatuzumab for Relapsed or Recurrent HNSCC

September 23rd 2022

The FDA has granted a fast track designation to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma.

Vogelzang, 2018 Giants of Cancer Care® Winner, Dies at 72

September 23rd 2022

Nicholas J. Vogelzang, MD, a world-renowned genitourinary oncologist and investigator and the 2018 Giants of Cancer Care® award winner in GU cancer, died on September 20, 2022. He was 72.

Duvelisib Loses Support for CLL/SLL Indication Following ODAC Meeting

September 23rd 2022

In an 8 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the final overall survival data submitted did not demonstrate a strong enough benefit-risk ratio for duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least 2 prior therapies.

Rituximab Maintenance Following First-line BR/R-CHOP Offers Significant Real-World Benefits in MCL

September 23rd 2022

Maintenance treatment with rituximab following first-line treatment with rituximab plus bendamustine or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone produced an overall survival benefit in older patients with mantle cell lymphoma.

Narsoplimab Elicits High Response Rate, Improves Organ Function in HSCT-TMA

September 23rd 2022

Treatment with narsoplimab denoted high response rates and a significant improvement in laboratory thrombotic microangiopathy markers, translating to favorable overall survival in patients with hematopoietic stem cell transplantation–associated thrombotic microangiopathy.

Pebbles Fagan, Ph.D., MPH, Joins Leadership Team at UAMS Winthrop P. Rockefeller Cancer Institute

September 23rd 2022

Pebbles Fagan, Ph.D., MPH, has assumed the role of associate director for Cancer Prevention and Control for the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences.

FDA Panel Opposes Continued Approval of Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

September 22nd 2022

In a 14 to 2 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the benefit-risk profile of melphalan flufenamide is not favorable for the approved indicated population of patients with relapsed/refractory multiple myeloma.

ODAC Votes Against Poziotinib for HER2 Exon 20 Insertion–Mutated NSCLC

September 22nd 2022

In a 9 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the benefits of poziotinib do not outweigh its risks for the treatment of patients with HER2 exon 20 insertion–mutated non–small cell lung cancer.

Dostarlimab Provides Survival Benefits in dMMR Endometrial Cancer and Other Solid Tumors

September 22nd 2022

Single-agent dostarlimab showcased durable antitumor activity in patients with mismatch repair–deficient endometrial cancer and other solid tumors, with landmark estimates at various time points underscoring stable progression-free survival benefits in responders.

Intraperitoneal Chemotherapy Technique Aims to Dramatically Improve Outcomes in Gastric Carcinomatosis

September 22nd 2022

A novel approach to chemotherapy administration in advanced gastric cancer that has progressed to gastric carcinomatosis is poised to alter the treatment landscape and improve outcomes for this patient population.

Florida Cancer Specialists & Research Institute Welcomes Monique Sajjad, DO to Largo Diagnostic Clinic

September 22nd 2022

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Board-certified medical oncologist and hematologist Monique Sajjad, DO, a hospitalist with the statewide practice since 2018, is now providing care to patients at the Florida Cancer Specialists & Research Institute Largo Diagnostic Clinic, located at 1301 2nd Ave. SW, Suite 290, Largo, FL 33770.

China Green Lights Olaparib for First-line Maintenance in HRD+ Advanced Ovarian Cancer

September 22nd 2022

Olaparib plus bevacizumab was approved in China as a first-line maintenance treatment for homologous recombination deficiency–positive ovarian cancer following a response to platinum-based chemotherapy plus bevacizumab.

Clinical Trials Aim to Bring Zenocutuzumab to Patients with NRG1+ Cancers

September 22nd 2022

Blocking ligand interaction of HER2 and HER3 in patients with NRG1 fusion–positive tumors has demonstrated a clinically feasible avenue to improve outcomes with the novel agent zenocutuzumab.

Zevor-cel Elicits 100% ORR in Heavily Pretreated Relapsed/Refractory Myeloma

September 22nd 2022

The BCMA-directed CAR T-cell therapy zevorcabtagene autoleucel demonstrated a 100% objective response rate in heavily pretreated patients with relapsed/refractory multiple myeloma

FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion+ Solid Tumors

September 21st 2022

The FDA has granted accelerated approval to selpercatinib for adult patients with locally advanced or metastatic solid tumors harboring a RET gene fusion that have progressed on or after previous systemic treatment or who have no satisfactory alternative treatment options.

FDA Grants Regular Approval to Selpercatinib for Locally Advanced or Metastatic RET+ NSCLC

September 21st 2022

The FDA has granted a regular approval to selpercatinib (Retevmo) for adult patients with locally advanced or metastatic non–small cell lung cancer harboring a RET gene fusion, as detected by an FDA-approved test.